

# Price and reimbursement policies

A. VILAR <sup>1</sup>, M. MAZARÍO <sup>1</sup>

<sup>1</sup> Scientific Affairs, UXAfarma, Barcelona, Spain

## INTRODUCTION

Generic medicines contribute to health systems' sustainability by its cost-efficiency. Public policies' promoting the use of generics have led to significant healthcare-related savings in European countries, but desired market penetration is not yet achieved.

## AIM


To describe generics pricing and reimbursement (PR) policies of 7 European countries which have reported high generics uptake and evaluate the policies which led to higher rates of generics use.

## METHOD

Pubmed and Google Scholar searches were performed using the following terms: generic medicines, reimbursement, pricing, policies.

## RESULTS

Reimbursed pharmaceutical market shares for generics (% volume) in European countries from 2010 to 2018. Norway and Sweden have missing data<sup>1</sup>



## CONCLUSIONS

- Medicines are more expensive in Germany but readily accessible, while in UK the wait is longer, but prices are lower.
- It seems that there is no standard procedure or policy for combination of measures.
- To obtain the most from generics, implemented policies should be tailored to each country specific health care setting

Country	Shares (volume %) (2017) <sup>1</sup>	Pricing system <sup>2</sup>	Reimbursement <sup>2</sup>	INN prescription <sup>2</sup>	Generics substitution <sup>2</sup>
France	30	Reference pricing	Reference groups (ATC 5)	Mandatory	Recommended
Germany	82	Reference pricing and value-based pricing	Reference groups and maximum refundable price	Recommended	Mandatory (except OTCs)
Netherlands	75	Reference pricing	Reference groups	Recommended	Recommended
Norway	49 <sup>3</sup>	Reference pricing	Reference groups (ATC 5)	Recommended	Recommended
Spain	47	Reference pricing	Reference groups (ATC 5)	Mandatory	Mandatory
Sweden	49 (2016) <sup>3</sup>	Value-based pricing	Reimbursement scheme (prescription-only)	Not allowed	Mandatory
United Kingdom	85	Market competition	Category schemes (Drug tariff)	Recommended	Not allowed

## REFERENCES

1. OECD, "Pharmaceutical market", *OECD Health Statistics* (database), 2020 <https://doi.org/10.1787/data-00545-en> (accessed on 21 August 2020).
2. <https://www.globallegalinsights.com/practice-areas/pricing-and-reimbursement-laws-and-regulations>
3. Vogler, Sabine & Haasis, Manuel & Zimmerman, Nina. (2019). Pharmaceutical pricing and reimbursement policies in 47 PPR1 network member countries.

## ACKNOWLEDGEMENTS

UXA FARMA S.A. team.

## CONTACT INFORMATION

Andrea Vilar: [avilar@uxafarma.com](mailto:avilar@uxafarma.com)  
Manuel Mazarío: [mmazario@uxafarma.com](mailto:mmazario@uxafarma.com)  
Av. San Francisco Javier, 24, 41018 Sevilla  
955 29 22 90